Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The UK's National Institute for Health and Care Excellence (NICE) has issued its Appraisal Consultation Document (ACD) recommending Bayer HealthCare's Xarelto (rivaroxaban) 2.5mg twice daily as an option for secondary prevention in acute coronary syndrome (ACS).
Subscribe to our email newsletter
The positive ACD is based on a thorough review of the clinical effectiveness of 2.5mg rivaroxaban twice daily in the randomized controlled landmark ATLAS ACS 2 TIMI 51 trial.
In the trial, Xarelto has shown significant advantages in the secondary prevention of ACS in patients with elevated cardiac biomarkers without prior stroke or transient ischemic attack (TIA).
Over dual antiplatelet therapy, it is observed that patient outcomes have been improved with the use of Xarelto as a treatment option.
NICE has recommended the drug as an option for preventing blood clots in people who have had a heart attack as a result of a blockage or narrowing in one of the blood vessels in the heart.
Bayer medical director Dr Luis Felipe Graterol said patients with ACS remain at risk even though there have been a number of advances in treatment over the past few years, including newer antiplatelet agents.
"This is evidenced by the high incidence of cardiovascular death, myocardial infarction and stroke in patients following an ACS event," Graterol said.
"Rivaroxaban offers an option for secondary prevention in this patient group, and we hope that selected patients in the UK will be able to benefit from this advance in therapy."